Goldman Sachs
RLYB icon

Goldman Sachs’s Rallybio RLYB Stock Holding History

Goldman Sachs’s Portfolio RLYB Stock Details RLYB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-22,650
Closed -$243K – 6029
2024
Q2 		$243K Buy
22,650
+20,995
+1,269% +$285K ﹤0.01% 5186
2024
Q1 		$24.5K Sell
1,655
-722
-30% -$10.1K ﹤0.01% 5379
2023
Q4 		$45.5K Buy
2,377
+565
+31% +$13.8K ﹤0.01% 5388
2023
Q3 		$48.8K Sell
1,812
-3,945
-69% -$171K ﹤0.01% 5278
2023
Q2 		$261K Buy
5,757
+3,185
+124% +$156K ﹤0.01% 5081
2023
Q1 		$118K Sell
2,572
-34
-1% -$1.76K ﹤0.01% 5431
2022
Q4 		$137K Sell
2,606
-1,584
-38% -$93.5K ﹤0.01% 5410
2022
Q3 		$485K Sell
4,190
-540
-11% -$48.1K ﹤0.01% 5000
2022
Q2 		$285K Buy
4,730
+2,819
+148% +$212K ﹤0.01% 5450
2022
Q1 		$107K Buy
1,911
+278
+17% +$23K ﹤0.01% 6089
2021
Q4 		$125K Buy
+1,633
New +$190K ﹤0.01% 6073

Other funds holding RLYB

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs's RLYB Position: Q3 2024 in Review

Goldman Sachs sold out of Rallybio (RLYB) in Q3 2024, closing a stake of 22,650 shares — an estimated $243K sold.

Goldman Sachs first reported a position in RLYB in Q4 2021 and held it in 11 quarters. The position peaked at $485K in Q3 2022. 49 funds tracked by Wall St. Rank hold RLYB as of Q3 2024.

  • Goldman Sachs reported no remaining Rallybio position as of Q3 2024 after selling out during the quarter.
  • Goldman Sachs sold 22,650 Rallybio shares in Q3 2024, an estimated $243K.
  • Goldman Sachs first reported a position in Rallybio in Q4 2021 and held it in 11 quarters.
  • Goldman Sachs's Rallybio position peaked at $485K in Q3 2022.
  • 49 funds tracked by Wall St. Rank held Rallybio as of Q3 2024.

Based on Goldman Sachs's 13F filing for Q3 2024, filed 14 Nov 2024.